Arrivederci, GINA
By Alex Philippidis,
Genetic Engineering & Biotechnology News
| 02. 04. 2013
Yaniv Erlich, Ph.D., and his research team at the Whitehead Institute hoped to start a conversation when they published their study in Science showing that all they needed to identify nearly 50 individuals who had submitted personal genetic material for genomic studies was just a computer, an Internet connection, and publicly accessible online resources.
That conversation has raised many of the right questions when it comes to privacy of genetic information. Answers, however, remain elusive despite the study and other recent developments in addressing the issue of genetic privacy, including publication last fall of a report by the U.S. Presidential Commission for the Study of Bioethical Issues.
The commission’s report, Privacy and Progress in Whole Genome Sequencing, stressed that individual interests in privacy must be respected and secured to realize the promise of whole genome sequencing in advancing clinical care and the greater public good.
One key recommendation calls for Washington to join states in hammering out “a consistent floor of protections” ensuring security for whole-genome sequence data, rather than the limited approach of the Genetic Information Nondiscrimination Act...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...